Comprehensive Review on CNPY2 (MSAP) as a Drug Target and Biomarker

Target Name: CNPY2

NCBI ID: G10330

CNPY2

Comprehensive Review on CNPY2 (MSAP) as a Drug Target and Biomarker

Abstract:

CNPY2 (Mesothelin-Specific Antigen-Purified Y2) is a protein that is expressed in various tissues and has been recognized as a potential drug target and biomarker. This review summarizes the current understanding of CNPY2, its expression, potential drug targets, and applications as a biomarker.

Introduction:

CNPY2 is a protein that is expressed in various tissues, including the placenta, lung, liver, and heart. It is a member of the mesothelin family, which is known to be involved in cell signaling and adhesion. The identification of potential drug targets and biomarkers in this family has significant implications for the development of new therapeutic approaches for various diseases.

Current understanding of CNPY2:

CNPY2 is a 25kDa protein that is expressed in various tissues, including the placenta, lung, liver, and heart. It is a member of the mesothelin family, which is characterized by the presence of a unique transmembrane domain and a potential N-terminal secretory domain. The N-terminal region of CNPY2 contains a unique calineptrine domain that is involved in its stability and localization to the cell surface.

Expression of CNPY2:

CNPY2 is expressed in various tissues and has been detected in various biological samples, including placenta, lung, liver, and heart. It is a cell surface protein that can be targeted by small molecules, antibodies, or viruses due to its unique structure and expression pattern. The expression of CNPY2 has been shown to be regulated by various factors, including growth factors, chemokines, and viral infection.

Potential Drug Targets:

CNPY2 has been recognized as a potential drug target due to its unique structure and expression pattern. The calineptrine domain of CNPY2 has been shown to be involved in its stability and localization to the cell surface, making it a potential target for small molecules or antibodies that can modulate its stability or localization. Additionally, the N-terminal region of CNPY2 contains a unique domain that is involved in its interaction with various signaling pathways, making it a potential target for small molecules or antibodies that can modulate its interaction with these signaling pathways.

Biomarker Potential:

CNPY2 has also been recognized as a potential biomarker due to its unique expression pattern and structure. The expression of CNPY2 has been shown to be regulated by various factors, including growth factors, chemokines, and viral infection. This regulation suggests that CNPY2 may be a useful biomarker for the diagnosis and monitoring of various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases.

Conclusion:

CNPY2 is a protein that has been identified as a potential drug target and biomarker due to its unique structure and expression pattern. The calineptrine domain of CNPY2 has been shown to be involved in its stability and localization to the cell surface, making it a potential target for small molecules or antibodies that can modulate its stability or localization. Additionally, the N-terminal region of CNPY2 contains a unique domain that is involved in its interaction with various signaling pathways, making it a potential target for small molecules or antibodies that can modulate its interaction with these signaling pathways. Further research is needed to determine the efficacy and safety of targeting CNPY2 as a drug or biomarker in clinical trials.

Protein Name: Canopy FGF Signaling Regulator 2

Functions: Positive regulator of neurite outgrowth by stabilizing myosin regulatory light chain (MRLC). It prevents MIR-mediated MRLC ubiquitination and its subsequent proteasomal degradation

The "CNPY2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CNPY2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets